Profile of cancer patients and their opinions regarding the use of drugs not approved by the Sanitary Surveillance National Agency
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | HU Revista (Online) |
Texto Completo: | https://periodicos.ufjf.br/index.php/hurevista/article/view/27398 |
Resumo: | Introduction: ANVISA is the Brazilian national agency responsible for the authorization and regulation of the sale and use of medicines and monitors its therapeutic and adverse effects. In the middle of this scenario are patients undergoing cancer treatment, liable to several traditional or novel drugs (often not yet approved by the Agency) which are sometimes targeted by new therapies that have not yet been regulated. Objectives: To trace the profile of patients under chemotherapy, as well as their possible use of drugs not yet approved by ANVISA. Material and methods: A cross-sectional study was carried out using a structured questionnaire in 400 cancer patients under follow-up at specialized institutions, where quantitative variables were evaluated, followed by descriptive and exploratory statistical analysis with frequency, trend and dispersion measures, all with numerical significance. Results: A total of 244 women and 166 men were observed, mean age 59 years ± 13.5. 74.25% would not use drugs not approved by ANVISA, while 25.75% would use them. 63% of those who would use new drugs are less than 59 years old. The majority had average income between 1 and 3 minimum wages, with more than half having studied only until elementary school. 62% do not know what ANVISA is, nor is it aware of its role. Still, it is finally noted that 61% of patients would participate in a hypothetical research to approve a new drug. Conclusion: It is possible to say that determinant factors to use drugs not approved by ANVISA are: being younger than 59 years old, female, absence of other therapeutic options and side effects of the current drugs. Also, 92.3% of the patients interviewed are aware of the risks of using medicines not approved by ANVISA. |
id |
UFJF-8_c8f50bf3395d87ea4ee75a0f098817dc |
---|---|
oai_identifier_str |
oai:periodicos.ufjf.br:article/27398 |
network_acronym_str |
UFJF-8 |
network_name_str |
HU Revista (Online) |
repository_id_str |
|
spelling |
Profile of cancer patients and their opinions regarding the use of drugs not approved by the Sanitary Surveillance National AgencyPerfil de pacientes oncológicos e suas opiniões quanto ao uso de medicamentos não aprovados pela Agência Nacional de Vigilância SanitáriaBrazilian Health Surveillance AgencyPopulationDrug TherapySickness Impact ProfileAgência Nacional de Vigilância SanitáriaPopulaçãoTratamento FarmacológicoPerfil de Impacto da DoençaIntroduction: ANVISA is the Brazilian national agency responsible for the authorization and regulation of the sale and use of medicines and monitors its therapeutic and adverse effects. In the middle of this scenario are patients undergoing cancer treatment, liable to several traditional or novel drugs (often not yet approved by the Agency) which are sometimes targeted by new therapies that have not yet been regulated. Objectives: To trace the profile of patients under chemotherapy, as well as their possible use of drugs not yet approved by ANVISA. Material and methods: A cross-sectional study was carried out using a structured questionnaire in 400 cancer patients under follow-up at specialized institutions, where quantitative variables were evaluated, followed by descriptive and exploratory statistical analysis with frequency, trend and dispersion measures, all with numerical significance. Results: A total of 244 women and 166 men were observed, mean age 59 years ± 13.5. 74.25% would not use drugs not approved by ANVISA, while 25.75% would use them. 63% of those who would use new drugs are less than 59 years old. The majority had average income between 1 and 3 minimum wages, with more than half having studied only until elementary school. 62% do not know what ANVISA is, nor is it aware of its role. Still, it is finally noted that 61% of patients would participate in a hypothetical research to approve a new drug. Conclusion: It is possible to say that determinant factors to use drugs not approved by ANVISA are: being younger than 59 years old, female, absence of other therapeutic options and side effects of the current drugs. Also, 92.3% of the patients interviewed are aware of the risks of using medicines not approved by ANVISA.Introdução: A Agência Nacional de Vigilância Sanitária (ANVISA) é o órgão nacional responsável pela autorização e regulamentação de venda e uso de medicamentos e monitora seus efeitos terapêuticos e adversos. Em meio a esse cenário, encontram-se os pacientes sob tratamento oncológico, sujeitos ao uso de diversos fármacos tradicionais ou inovadores (frequentemente ainda não aprovados pela Agência), que são, por vezes, indicados para terapias ainda não regulamentadas. Objetivos: Avaliar o perfil de pacientes oncológicos que estão ou estiveram em quimioterapia e/ou radioterapia e/ou outras terapias, o conhecimento destes sobre a ANVISA e suas funções, além das possibilidades de uso de medicamentos não aprovados pelo órgão e, secundariamente, de participação em uma pesquisa experimental hipotética. Material e Métodos: Estudo transversal descritivo com variáveis quantitativas, ao se aplicar questionário estruturado em 400 pacientes em tratamento oncológico sob acompanhamento em instituições especializadas, com análise estatística de medidas de frequência, tendência e dispersão. Resultados: Foram entrevistados 166 homens e 244 mulheres, com idade média de 59 anos ± 13.5. Não usariam medicamentos não aprovados pela ANVISA 74.25% dos pacientes, enquanto 25.75% fariam uso. A renda média prevalente foi de um a três salários mínimos, com mais da metade dos entrevistados tendo estudado até o ensino fundamental. Dos participantes, 62% não sabem o que é a ANVISA e tampouco têm conhecimento sobre seu papel. Ainda, 92,3% dos pacientes entrevistados estão cientes dos riscos de se usar medicamentos não aprovados pela Agência, e 61% participariam de uma pesquisa hipotética para aprovar um novo medicamento. Conclusão: São fatores determinantes para o uso de medicamentos não aprovados pela ANVISA: ter até 59 anos, ausência de outras opções terapêuticas e os efeitos colaterais dos atuais fármacos. Além disso, a maioria dos entrevistados estaria disposta a participar de uma pesquisa experimental para aprovação de uma nova medicação.Editora UFJF2020-05-25info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtOrapplication/pdfhttps://periodicos.ufjf.br/index.php/hurevista/article/view/2739810.34019/1982-8047.2020.v46.27398HU Revista; v. 46 (2020); 1-101982-80470103-3123reponame:HU Revista (Online)instname:Universidade Federal de Juiz de Fora (UFJF)instacron:UFJFporhttps://periodicos.ufjf.br/index.php/hurevista/article/view/27398/20587Copyright (c) 2020 José Antônio Chehuen Neto, Beatriz Stephan Farhat Jorge, Filipe Raimundi Sampaio de Oliveira, Lucas Alves de Almeida, Nathália Couri Vieira Marques, Renato Erothildes Ferreira, Sávio Dornelas Brederinfo:eu-repo/semantics/openAccessChehuen Neto, José AntônioStephan Farhat Jorge, BeatrizRaimundi Sampaio de Oliveira, FilipeAlves de Almeida, LucasCouri Vieira Marques, NatháliaErothildes Ferreira, RenatoDornelas Breder, Sávio2020-11-20T19:42:11Zoai:periodicos.ufjf.br:article/27398Revistahttps://periodicos.ufjf.br/index.php/hurevistaPUBhttps://periodicos.ufjf.br/index.php/hurevista/oairevista.hurevista@ufjf.edu.br1982-80470103-3123opendoar:2020-11-20T19:42:11HU Revista (Online) - Universidade Federal de Juiz de Fora (UFJF)false |
dc.title.none.fl_str_mv |
Profile of cancer patients and their opinions regarding the use of drugs not approved by the Sanitary Surveillance National Agency Perfil de pacientes oncológicos e suas opiniões quanto ao uso de medicamentos não aprovados pela Agência Nacional de Vigilância Sanitária |
title |
Profile of cancer patients and their opinions regarding the use of drugs not approved by the Sanitary Surveillance National Agency |
spellingShingle |
Profile of cancer patients and their opinions regarding the use of drugs not approved by the Sanitary Surveillance National Agency Chehuen Neto, José Antônio Brazilian Health Surveillance Agency Population Drug Therapy Sickness Impact Profile Agência Nacional de Vigilância Sanitária População Tratamento Farmacológico Perfil de Impacto da Doença |
title_short |
Profile of cancer patients and their opinions regarding the use of drugs not approved by the Sanitary Surveillance National Agency |
title_full |
Profile of cancer patients and their opinions regarding the use of drugs not approved by the Sanitary Surveillance National Agency |
title_fullStr |
Profile of cancer patients and their opinions regarding the use of drugs not approved by the Sanitary Surveillance National Agency |
title_full_unstemmed |
Profile of cancer patients and their opinions regarding the use of drugs not approved by the Sanitary Surveillance National Agency |
title_sort |
Profile of cancer patients and their opinions regarding the use of drugs not approved by the Sanitary Surveillance National Agency |
author |
Chehuen Neto, José Antônio |
author_facet |
Chehuen Neto, José Antônio Stephan Farhat Jorge, Beatriz Raimundi Sampaio de Oliveira, Filipe Alves de Almeida, Lucas Couri Vieira Marques, Nathália Erothildes Ferreira, Renato Dornelas Breder, Sávio |
author_role |
author |
author2 |
Stephan Farhat Jorge, Beatriz Raimundi Sampaio de Oliveira, Filipe Alves de Almeida, Lucas Couri Vieira Marques, Nathália Erothildes Ferreira, Renato Dornelas Breder, Sávio |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Chehuen Neto, José Antônio Stephan Farhat Jorge, Beatriz Raimundi Sampaio de Oliveira, Filipe Alves de Almeida, Lucas Couri Vieira Marques, Nathália Erothildes Ferreira, Renato Dornelas Breder, Sávio |
dc.subject.por.fl_str_mv |
Brazilian Health Surveillance Agency Population Drug Therapy Sickness Impact Profile Agência Nacional de Vigilância Sanitária População Tratamento Farmacológico Perfil de Impacto da Doença |
topic |
Brazilian Health Surveillance Agency Population Drug Therapy Sickness Impact Profile Agência Nacional de Vigilância Sanitária População Tratamento Farmacológico Perfil de Impacto da Doença |
description |
Introduction: ANVISA is the Brazilian national agency responsible for the authorization and regulation of the sale and use of medicines and monitors its therapeutic and adverse effects. In the middle of this scenario are patients undergoing cancer treatment, liable to several traditional or novel drugs (often not yet approved by the Agency) which are sometimes targeted by new therapies that have not yet been regulated. Objectives: To trace the profile of patients under chemotherapy, as well as their possible use of drugs not yet approved by ANVISA. Material and methods: A cross-sectional study was carried out using a structured questionnaire in 400 cancer patients under follow-up at specialized institutions, where quantitative variables were evaluated, followed by descriptive and exploratory statistical analysis with frequency, trend and dispersion measures, all with numerical significance. Results: A total of 244 women and 166 men were observed, mean age 59 years ± 13.5. 74.25% would not use drugs not approved by ANVISA, while 25.75% would use them. 63% of those who would use new drugs are less than 59 years old. The majority had average income between 1 and 3 minimum wages, with more than half having studied only until elementary school. 62% do not know what ANVISA is, nor is it aware of its role. Still, it is finally noted that 61% of patients would participate in a hypothetical research to approve a new drug. Conclusion: It is possible to say that determinant factors to use drugs not approved by ANVISA are: being younger than 59 years old, female, absence of other therapeutic options and side effects of the current drugs. Also, 92.3% of the patients interviewed are aware of the risks of using medicines not approved by ANVISA. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-05-25 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion ArtOr |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://periodicos.ufjf.br/index.php/hurevista/article/view/27398 10.34019/1982-8047.2020.v46.27398 |
url |
https://periodicos.ufjf.br/index.php/hurevista/article/view/27398 |
identifier_str_mv |
10.34019/1982-8047.2020.v46.27398 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://periodicos.ufjf.br/index.php/hurevista/article/view/27398/20587 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Editora UFJF |
publisher.none.fl_str_mv |
Editora UFJF |
dc.source.none.fl_str_mv |
HU Revista; v. 46 (2020); 1-10 1982-8047 0103-3123 reponame:HU Revista (Online) instname:Universidade Federal de Juiz de Fora (UFJF) instacron:UFJF |
instname_str |
Universidade Federal de Juiz de Fora (UFJF) |
instacron_str |
UFJF |
institution |
UFJF |
reponame_str |
HU Revista (Online) |
collection |
HU Revista (Online) |
repository.name.fl_str_mv |
HU Revista (Online) - Universidade Federal de Juiz de Fora (UFJF) |
repository.mail.fl_str_mv |
revista.hurevista@ufjf.edu.br |
_version_ |
1796798243198205952 |